Antibiotic Regimens With Reliable Coverage for Pseudomonas aeruginosa and Enterococcus faecalis
Reliable empiric urinary coverage for both Pseudomonas aeruginosa and Enterococcus faecalis is achieved by combining (1) an antipseudomonal beta-lactam agent active against Pseudomonas with (2) an Enterococcus-targeted agent active against E. faecalis. [1], [2]
Medication Selection Algorithm
Pseudomonas coverage
Antipseudomonal beta-lactams are used for P. aeruginosa coverage:
- Piperacillin-tazobactam [1]
- Cefepime [1]
- Ceftolozane-tazobactam (when available/indicated for resistant Pseudomonas) [3]
- Ceftazidime-avibactam (when available/indicated for resistant Pseudomonas) [3]
- Carbapenems (imipenem or meropenem) in selected circumstances with early culture evidence of multidrug-resistant organisms [3]
Enterococcus faecalis coverage
Enterococcus-targeted therapy is added when E. faecalis coverage is required:
- Ampicillin (preferred for E. faecalis susceptibility) [2]
Key Evidence Supporting This Recommendation
-
E. faecalis has high susceptibility to ampicillin in clinical urinary isolates in stewardship guidance for UTIs. [2]
-
Antipseudomonal beta-lactams used for empiric severe Gram-negative coverage include piperacillin-tazobactam and cefepime. [1]
Monotherapy Versus Combination Therapy
-
Antipseudomonal beta-lactam monotherapy is not reliably adequate for E. faecalis coverage across all susceptibility patterns. [2]
-
Combination therapy is used for reliable dual coverage by adding ampicillin to an antipseudomonal beta-lactam. [2]
Important Clarifications or Nuances
-
Enterococcus spp. may represent colonization or contamination in urine culture in some settings, including catheterized patients, so Enterococcus-directed therapy should be limited to symptomatic infection when feasible. [2]
-
Empiric regimens for complicated UTI should be selected using severity and patient-specific resistant-organism risk factors, with de-escalation based on culture results. [4]
Initiation Thresholds or Indications
- This dual-coverage approach is indicated when empiric therapy is required for complicated UTI or pyelonephritis with risk for resistant Gram-negative organisms (including Pseudomonas) and when E. faecalis coverage is needed based on prior culture history or clinical risk. [4]
Common Pitfalls to Avoid
-
Avoiding de-escalation after culture results increases exposure to unnecessary antibiotics. [4]
-
Nitrofurantoin is not appropriate for pyelonephritis or complicated UTI due to inadequate renal tissue penetration. [5]
Target Goals of Therapy
-
Culture-directed de-escalation is prioritized to reduce recurrence and improve clinical cure while optimizing antibiotic effectiveness. [4]
-
Therapy should be narrowed to the least-broad active regimen once susceptibilities are available. [4]
Practical Empiric Options Used for Dual Coverage
-
Piperacillin-tazobactam plus ampicillin for empiric dual coverage of P. aeruginosa and E. faecalis. [1], [2]
-
Cefepime plus ampicillin for empiric dual coverage when cefepime is selected for Pseudomonas coverage. [1], [2]
-
Ceftolozane-tazobactam plus ampicillin in settings where advanced anti-Pseudomonas beta-lactams are selected based on resistance risk. [3], [2]